Kornimate/medical-research-clean huggingface dataset:
study on the antibody level against sars-cov-2 （covid-19）in dazhu county in 2023

Conditions: COVID-19

Summary: about 15,000 to 25,000 subjects will be screened. their information will be collected, venous blood will be sampled, their serum antibody levels will be detected, and the incidence of covid-19 wil be followed up.

data of the following will be collected: 1. demographic data,including name, gender, ethnic groups, id card number (age automatically calculated), height/weight (automatic bmi calculation); 2. previous disease/surgical history; 3. previous covid-19 infections; 4. covid-19 vaccination history; 5. infection after this screening; 6. screening information for covid-19 antibodies. atibody level against sars-cov-2 will be test.

Eligibility criteria:
inclusion criteria: * the age when signing icf should be ≥3 year, male or female. * the subject and/or guardian or client of both parties are able to sign a written icf and voluntarily participate in the trial, fully understand the trial procedure, the risks of participating in the study. * healthy subjects or subjects with stable underlying diseases. stable underlying diseases were defined as those who were in stable condition at least 3 months before inclusion in the study, had no significant change in treatment regimen and had not been admitted to hospital due to disease progression. exclusion criteria: * a history of contraindications for venous blood collection such as thrombocytopenia or other clotting disorders. * current severe or uncontrollable cardiovascular disease, endocrine disease, blood and lymphatic system disease, liver and kidney disease, respiratory system disease, metabolic and skeletal system disease, or malignancy. * if it is not in line with the benefit maximization of the subjects, the investigator determines that it is not suitable to participate in clinical research.
a 28-week open label extension study evaluating safety and tolerability of donepezil hydrochloride in subjects with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: this is a multi-center, open-label study of 28 weeks duration in subjects with mild cognitive impairment who have completed the double-blind study (e2020-a001-412).


Eligibility criteria:
inclusion criteria: 1. age range: adult subjects (45 to 90 years of age inclusive) 2. sex distribution: men and women. women of child-bearing potential (\<1 year post menopausal) must be practicing effective contraception and have negative serum b-hcg at screening. \[women who are breast-feeding are excluded.\] 3. subjects must have completed the one year, double-blind core trial (e2020-a001-412). 4. a completed diagnostic worksheet at the end of the double-blind core trial (e2020-a001-412) indicating no conversion to alzheimer's disease or dementia. 5. health: generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane). 6. the subject must be expected to complete the entire study. 7. subjects must be sufficiently fluent in english. 8. subjects must have an informant who has daily contact with the subject (e.g., an average of 10 or more hours per week), can observe for possible adverse events and will accompany the subject to all visits. 9. clinical laboratory values must be within normal limits, or if abnormal, judged clinically insignificant by the investigator (not likely to cause cognitive impairment or medical instability). exclusion criteria: 1. subjects who have not completed or have terminated early from the one year, double-blind core trial (e2020-a001-412). 2. any subject without a completed diagnostic worksheet from week 51 of the core double-blind trial (e2020-a001-412). 3. any subject with a completed diagnostic worksheet from week 51 of the core double-blind trial (e2020-a001-412) indicating conversion to alzheimer's or other dementia. 4. subjects with uncontrolled hypertension (sitting systolic \>= 160mmhg and/or diastolic \>=95mmhg) as assessed by the investigator, regardless of whether or not the subject is taking anti-hypertensive medications. 5. subjects with a history of malignant neoplasms treated within five years prior to study entry (other than basal or squamous cell carcinoma of the skin); current evidence of malignant neoplasm; or recurrent or matastatic disease. 6. subjects who have suffered a severe infection or a major surgical procedure within three months prior to baseline. 7. subjects who may not be able to comply with the protocol. 8. subjects with known hypersensitivity to piperidine derivatives or acetylcholinesterase(ache)inhibitors. 9. subjects with diabetes mellitis not controlled by diet and/or medication with a random serum glucose value of \>170mg/dl. 10. any condition which would make the subject, in the opinion of the investigator, unsuitable for the study. 11. subjects who do not have a reliable informant (e.g., the informant has contact with the subject less than 10 hours per week).

Keywords: mild cognitive impairment
nudges to improve health behaviors that limit covid-19 spread

Conditions: Health Behavior; COVID-19

Summary: this investigation is a randomized intervention trial that evaluates behavioral nudges (bn) to increase hand washing behavior and subsequently reduce covid-19 spreading to a targeted high-risk patient population based in wisconsin.


Eligibility criteria:
inclusion criteria: * age 18 years or older * provision of signed and dated informed consent form * willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study * has at least 1 risk factor associated with covid-19 documented in their electronic medical record * followed by (i.e., actively receiving care) from targeted mcw specialties (internal medicine, obgyn, surgery) * access to necessary resources for participating in a technology-based activities (i.e., internet access + mobile phone or computer to complete online survey) * maintains a personal address where study materials can be shipped and where participant lives full time exclusion criteria: * previous covid-19 diagnosis or positive covid-19 test result documented in their electronic medical record * current participation in another treatment or intervention study associated with covid-19 * previous documented obsessive-compulsive disorder diagnosis in their electronic medical record * non-english speaker * patients hospitalized or incapacitated at onset of potential enrollment * no access to electronic platform with internet (e.g., smartphone, tablet, computer)
local culture-based nutrition education intervention on iron supplement tablets (ist) consumption compliance in female adolescents at ogan komering ilir regency: a quasi-experimental protocol study

Conditions: Anemia; Iron Deficiency Anemia

Summary: the goal of this clinical trial is to test the impact of a local culture-based nutritional education intervention on ist consumption compliance among female adolescents in the ogan komering ilir regency. the main questions it aims to answer are: a to identify information for the development of a local culture-based nutrition education model and to build a ready-to-implement local culture-based nutrition education model. b. to evaluate the implementation of the anemia prevention and control program among female adolescents in ogan komering ilir regency. c. to test the impact of the local culture-based nutrition education model on the improvement of knowledge, attitude, and ist consumption compliance among female adolescents. participants will received ist and local culture-based nutrition education. researchers will compare control group received ist as the ministry of health's program for the prevention of anemia with a subsidy for providing ist


Eligibility criteria:
inclusion criteria: * public schools have received the ist program from the government, and the distance between schools is at least 10 kilometers * students enrolled in grade 11, age range 15-17 years, menstruating, owning a smartphone, having an instagram account, and obtaining parental approval to participate in this study exclusion criteria: * schools that are currently the object of another study and are difficult to reach (remote areas) * students who have a bmi value≤ -3 sd and do not watch complete educational videos for the sample in the intervention group

Keywords: anemia iron supplement tablets
quantification of myocardial fibrosis in aortis stenosis

Conditions: Aortic Valve Stenosis; Myocardial Fibrosis

Summary: this study is a long term follow-up of patients that were included as part of a previous study (nct03422770), where patients with aortic stenosis and healthy controls went through echocardiography, cardiac mri, long-term ecg-recording, blood tests and quality of life assessment. echocardiography included high frame ultrasound for detection of natural mechanical waves, and the measured speed of these waves were used as a marker of the extent of myocardial fibrosis. up to five years have now passed since inclusion at baseline, and a proportion of the patients in the cohort have undergone aortic valve replacement at some point. in this study, the investigators will repeat the cardiac imaging (echocardiography and cardiac mri), ecg and blood test, to assess long-term changes in myocardial fibrosis in aortic stenosis patients.

high frame rate ultrasound with quantification of myocardial mechanical wave velocities provides a new approach to evaluation of myocardial stiffness. principle: an elastic medium (the left ventricle) is incited by a force (naturally occuring mechanical wave generated by atrial contraction and/or closure of mitral and aortic valve), and the resulting oscillation wave propagates through the medium with a speed that depends only on the density and stiffness of the medium. if the density of the medium is known, measuring the propagation velocity of the wave is the same as measuring the stiffness of the medium. there is a lack of longitudinal data in this research area. a follow-up study of the described cohort, will add valuable insight into high frame rate ultrasound as a potential tool to quantify myocardial fibrosis in heart failure patient, and to monitor any changes from baseline.

Eligibility criteria:
inclusion criteria: * part of the initial cohort that were included in the baseline study * still able to undergo protocolled investigations * patients: mild, moderate or severe as exclusion criteria: * renal insufficiency * previously myocardial infarction (ecg, echocardiogram or hospital record) * severe valvular heart disease (except patients) * other cardiac disease known to cause myocardial fibrosis * severe hypertension * other medical conditions deterring protocolled investigation and follow-up * other medical conditions affecting 5-years prognosis (cancer, pulmonary disease) * severely reduced image-quality (echocardiography and mri)

Keywords: high frame rate echocardiography heart failure aortic stenosis cardiac mri prognosis quantification of severity
dermacyd silver frutal (lactic acid) - photo evaluation.

Conditions: Hygiene

Summary: primary objective: to demonstrate the absence of photoirritation and photosensitization potential of the product dermacyd silver frutal.


Eligibility criteria:
inclusion criteria: * phototype skin ii and iii integral skin test in the region * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion exclusion criteria: * lactation or pregnancy * use of antiinflammatory 30 days and/or immunossupression drugs for until 3 months before volunteers selection * diseases which can cause immunosuppresion, such as diabetes, hiv * use of photosensitivity drugs * history of sensitivity or photosensitivity for topic products * cutaneous active disease which can modify the study results * history or activity of photodermatosis * personal or family antecedents of cutaneous neoplasia photo induced * presence of injury precursor of cutaneous neoplasia, such as melanociticos nevus and actinic keratosis * intense exposure solar in the test region * use of new drugs and/or cosmetics during the study * previous participation in studies using the same product in test * relevant history or confirmation of alcohol or other drugs abuse * intolerance detected or suspected for some component of the sample tested * medecin or sponsor employees or their close family. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
impact of a nutritional supplement on the recovery of the nutritional status of patients with spontaneous hip fracture

Conditions: Hip Fractures; Malnutrition

Summary: multicenter, prospective, randomized, double-blind, interventional study with a nutritional supplement against placebo in a cohort of patients hospitalized for hip fracture.

hip fracture is a very prevalent pathology in the elderly population. it is estimated that 35-40% of people over 65 suffer a drop per year, and above 75 years this percentage is even higher, with hip fractures being one of the most serious consequences.with regard to malnutrition, the investigators know that aging carries an increased risk of suffering from decreased appetite and intake and changes in body composition. according to different series, the percentage of malnutrition in patients with hip fracture ranges from 13% to 60%. according to the hospital protocols in spain in elderly people with spontaneous hip fracture, it is important to perform a nutritional screening during the first 24-48 hours of admission, to evaluate their nutritional status and apply a dietary treatment. the irene study aims to determine whether phase angle and reactance, measured by electrical bioimpedance by vector analysis (biva) are related to functional recovery in patients with hip fracture.

Eligibility criteria:
inclusion criteria: * patients over 65 years old. * patients admitted to hospital by spontaneous hip fracture and requiring surgery. * patients who after hip intervention are included in rehabilitation protocols with outpatient rehabilitation plan. * patients who agree to participate by signing informed consent or their regular caregivers grant consent. exclusion criteria: * patients who have a hip fracture from high-impact trauma or secondary to bone pathology (such as neoplasm). * patients with concomitant diseases such as severe hepatic impairment, severe renal impairment, insulin-dependent diabetes melitus and decompensated diabetes mellitus. * patients who require clinical stabilization before surgery beyond 72 hours. * patients receiving emergency surgery. * patients with previous prostheses. * patients with pacemakers. * patients who are not likely to complete the follow-up.

Keywords: phase angle nutritional supplement
mguard stent and microcirculation

Conditions: Coronary Disease; Coronary Artery Disease; Coronary Atherosclerosis; Cardiovascular Diseases

Summary: nste-acs represents the most frequent indication for coronary angiography and percutaneous coronary intervention (pci) worldwide. pci permit to reestablished coronary flow but effectiveness of pci within thrombus containing lesions is limited by the risk of occurrence of distal embolization and no-reflow phenomenon. distal embolization lead to coronary microcirculation lesions. this complication is related to poor prognosis. mguard stent is a stainless-steel closed cell stent covered with an ultra-thin polymer mesh sleeve, which allows to prevent distal embolization during percutaneous coronary intervention in st-segment-elevation myocardial infarction. index of microcirculatory resistance (imr) is a validated method to assess coronary microcirculation. accordingly, the purpose of this study is to demonstrate that mguard micronet mesh-covered stent prevent distal embolization and microvascular reperfusion impairment during primary pci, compared with a bare metal stent (bms) and drug eluting stent (des) in patients with nste-acs, assessed by index of microcirculatory resistance.

guardiancory study is a multicentre, prospective, randomized, non inferiority, open-label trial with a planned inclusion of 52 patients with ste and nste acs and prescribed pci. patients will be randomized to benefiting either des /bms implantation (n=26) or mguard stent (n=26) on the culprit lesion. assessment of coronary microcirculation will be done by imr immediately after pci by using a pressure-temperature sensor-tipped coronary wire, thermodilution-derived.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patients affiliated to social security * patients with an nstemi or stemi (1) * thrombus containing coronary lesions on angiography (timi thrombus grade ≥ 3) * eligible patients for revascularization with angioplasty * patients consenting to participate in the study. exclusion criteria: * age \< 18 years * prior myocardial infarction * prior cabg * inability to comply with the protocol * major patient protected by law (article l1121-8), * person deprived of liberty (article l1121-8), * pregnant woman * breastfeeding women * patient with terminal illness, * terminal renal failure * allergy to iodine * adenosine's contraindications: asthmatic patients, second- or third-degree av block without a pacemaker or sick sinus syndrome. systolic blood pressure less than 90mmhg. recent use of dipyridamole or dipyridamole-containing medications, methyl xanthenes such as aminophylline caffeine or theobromine block the effect of adenosine and should be held for at least 12 hours prior to the test. known hypersensitivity to adenosine. unstable acute myocardial infarction or acute coronary syndrome.
evaluation of the effect of different doses dexmedetomidine infusion on lung mechanics and oxygenation in obese patients

Conditions: Obesity; Drug

Summary: • the objective of this study is to evaluate the effect of different doses of dexmedetomidine infusion intraoperative on lung mechanics and oxygenation regarding pao2/fraction of inspired oxygen), intraoperative oxygenation, lung compliance (static and dynamic), dead space, and paco2,heart rate, mean arterial blood pressure in obese patients undergoing laparoscopic cancer surgeries

dexmedetomidine is a selective agonist of α2receptorswhose tendency to α2 receptors is eight times more than that of clonidine. it also has powerful sedative, analgesic, anti-inﬂammatory, and organ protective properties. dexmedetomidine has favorable respiratory effects in humans. the effects of dexmedetomidine on oxygenation and lung mechanics had been investigated in obstructive lung disease. dexmedetomidine decreased dead space and improved both lung compliance and oxygenation in chronic obstructive pulmonary disease (copd) patients undergoing lung cancer surgery. morbidly obese patients are characterized by the high prevalence of restrictive lung disease.the study include 2 equal groups, each group is 35 patients: group a(n=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/kg lbw) bolus, followed by 0.5μg/kg/hour continuous infusion till the end of surgery and group b(n=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/kg lbw) bolus, followed by 0.3μg/kg/hour continuous infusion till the end of surgery.

Eligibility criteria:
inclusion criteria: * age 18-60years * obese patients bmi\>25 kg/meter square * patients undergoing laparoscopic cancer surgery. exclusion criteria: * heart failure * arrhythmias * severe liver or kidney impairment * patients with forced expiratory volume in 1 sec (fev1)/fvc \< 70% * heart block
clinical outcomes after acute pulmonary embolism

Conditions: Pulmonary Embolism

Summary: to investigate safety and effectiveness of pe treatment according to the decision of the multi-disciplinary pulmonary embolism response team (pert) and to define and optimize treatment indications, institutional algorithms and interventional techniques for pe.

this single-center cohort study is designed to retrospectively and prospectively collect treatment and outcome data related to patients with pe and after activation of the pert. treatment information and outcomes after advanced treatment modalities, including systemic thrombolysis, catheter directed thrombolysis and surgical embolectomy, will be collected. retrospective patient data will consist of treatment and health related outcomes of consecutive patients treated for acute and chronic pe between october 2017 and april 2020 (to assess the learning curve of the pert) and of patients receiving surgical embolectomy between january 2001 and april 2020. the retrospective data will be derived from the local institutional dataset and will be transferred to the study database. prospective patients will be included after may 2020.

Eligibility criteria:
inclusion criteria: * consecutive patients with pulmonary embolism matching the criteria for treatment according to the decision of the pert. * written informed consent exclusion criteria: * high probability of non-adherence to the follow up requirements
proximal- versus distal-prioritized robotic practice plus kinetic exergaming in stroke rehabilitation

Conditions: Stroke Rehabilitation

Summary: this research program aims at investigating the effects of upper-limb robotic therapy primed with interactive exergaming as an innovative hybrid regimen in stroke rehabilitation.

robotic therapy can potentially be a movement-based priming technique to promote rebalancing of cortical excitability and create an enriched neuroplastic environment by priming the brain to facilitate motor and functional recovery. the proximal priority and distal priority robotic priming techniques may bring differential effects. this proposed research project aims to: (1) examine the effects of proximal priority versus distal priority of bilateral robotic priming combined with exergaming on sensorimotor function, daily function, self-efficacy, quality of life, and motor control strategy in patients with stroke, (2) investigate the 3-month retention effects of the three approaches, and (3) identify the potential predictors of functionally relevant changes after therapy.

Eligibility criteria:
inclusion criteria: 1. a first ever-stroke≧3 months 2. age range between 20 to 80 years 3. baseline fugl-meyer assessment of upper extremity scale (fma-ue) between 18 to 56 4. no excessive muscle spasticity of the affected extremities (modified ashworth scale \< 3 at any joints) 5. able to follow examiners' commands and study instructions (mini-mental state examination score≧22) 6. can maintain a step-standing position for at least 30 seconds 7. can walk for at least 10 meters with or without device 8. no participation in further experimental rehabilitation or drug studies during the duration of the project exclusion criteria: 1. acute inflammation and pain 2. concomitant neurologic, neuromuscular or orthopedic conditions that may impede participation in this research.